Acesion Pharma

Acesion Pharma is a Danish biotech company founded in 2011 by scientists from NeuroSearch together with the venture funds Novo Seeds and SEED Capital Denmark II/DTU Symbion Innovation A/S.
Acesion Pharma aims to develop more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. AF mainly affects the elderly population and often causes a pronounced decrease in quality of life and furthermore increases the risk of stroke. Existing drug therapies generally have a limited effect or are associated with risk of serious adverse events. Therefore, there is a considerable need for developing better and safer drugs. Inhibition of SK channels, an ion channel present in the heart and with relevance for the cardiac rhythm, constitute a novel and promising drug target for the treatment of AF. Acesion Pharma aims to develop a first-in-class SK channel
inhibitor for the acute cardioversion of AF.